

FRI0638

### LUMBAR SPINE BONE MASS DENSITY AS A PREDICTOR OF FRACTURES IN PATIENTS WITH COELIAC DISEASE: AN OBSERVATIONAL STUDY

Mariam Gaddah<sup>1</sup>, Marwan Bukhari<sup>2</sup>. <sup>1</sup>Lancaster University, Lancaster, United Kingdom; <sup>2</sup>Royal Lancaster Infirmary, Lancaster, United Kingdom

**Background:** Previous studies have indicated that Lumbar spine Bone Mineral Density (BMD) could be used as an indicator to predict fractures in patients with coeliac disease (1). Patients with coeliac disease are at a higher risk of developing fragility fractures as a result of the underlying metabolic pathology. Despite previously highlighting the lumbar spine BMD usefulness in predicting fractures, score systems, like the FRAX score still has not acknowledged it. Additionally recent data suggested that using a ratio of Body mass index (BMI) to BMD could increase the predictive models for fracture.

**Objectives:** Through a large observational study, we set out to determine the various predictors of fractures in patients with coeliac disease. Age, gender and lumbar BMD were some of the factors that were considered in relation to fractures. This data was scrutinised to assess specifically the lumbar BMD's ability to predict fractures with and without using the BMI ratio.

**Methods:** A sample of 788 patients with coeliac disease referred for bone density estimation to a scanner in the North west of England from 2004-2010 was used to assess various predictors of fractures. Data were initially analysed using simple statistical analyses (chi-squared for categorical variables and T-test for continuous variables) to compare patients who had sustained a fracture to those that had not sustained a fracture.

The data was then subject to further analysis initially using univariate and then multivariate logistic regression models. Variables analysed included Lumbar spine L1-L4 BMD, BMI/BMD ratio, gender, age at scan, family history of fractures, alcohol, smoking and rheumatoid arthritis. In order to further assess the Lumbar spine BMD's vs BMI/BMD in predicting fractures, the data was further adjusted for age and gender and models compared using areas under the receiver operating characteristic (ROC) curve.

**Results:** Out of the 788 patients referred in the analysis period, 159 (20.2%) sustained a fracture. The mean age at the time of the scan was 55.4 (SD 14.4). A total of 576 (73.1%) were female and of those 127 (22%) had sustained a fracture. Female gender was significantly associated with fracture ( $p < 0.003$ ). Patients with fractures were older 59.2 years (SD 14) compared to 54 years (SD 14) ( $p < 0.001$ ). Using the multivariate model, it was evident that even after being adjusted for age and gender, the lumbar spine BMD was a good predictor of fractures (OR 0.08 95%CI 0.02,0.3). This performed better than the ratio of BMD/BMI. AUC 0.64 vs AUC 0.62.

**Conclusion:** The FRAX tool should consider using lumbar spine BMD as an indicator of fragility fractures in patients with coeliac disease. We have shown using both univariate and multivariate analyses that many factors are associated with fragility fractures, but the lumbar spine BMD was the best predictor. This study took the data another step further and adjusted the data for gender and age and added the ratio of BMI to BMD, but still reached a similar conclusion. Lumbar spine BMD should be taken into consideration with more care in this group of patients.

#### REFERENCES:

- [1] Sinha R, Bukhari M. THU0462 The Predictors of Fracture in Patients with Coeliac Disease: An Observational Study, *Annals of the Rheumatic Diseases* 2016;75:359.

**Disclosure of Interests:** Mariam Gaddah : None declared, Marwan Bukhari Speakers bureau: Bristol-Myers Squib, UCB celltech, Roche/Chugai, Pfizer, Abbvie, Merck, Mennarini, Sanofi-aventis, Eli-Lilly, Janssen and Novartis.

DOI: 10.1136/annrheumdis-2019-eular.4541

FRI0639

### A NOVEL SCREENING METHOD FOR HYDROXYCHLOROQUINE MACULOPATHY

Hani Hasan<sup>1,2,3</sup>, Khin Yein<sup>2</sup>, Tareq Mudawi<sup>4</sup>, Elizabeth Price<sup>2</sup>, Guy Smith<sup>3</sup>. <sup>1</sup>University of Edinburgh, Medical Sciences, Edinburgh, United Kingdom; <sup>2</sup>The Great Western Hospital, Swindon, United Kingdom; <sup>3</sup>The Royal College of Ophthalmologists, London, United Kingdom; <sup>4</sup>Royal College of Physicians, London, United Kingdom

**Background:** Hydroxychloroquine maculopathy is irreversible, primary prevention is done by early screening. Published data show that thinning of the retinal outer nuclear layer (ONL) is an early feature which has been described as "The flying saucer sign".

**Objectives:** To determine the effect of retinal outer nuclear layer thinning on the progression of hydroxychloroquine retinopathy.

**Methods:** We used a Heidelberg Spectralis(R) Spectral Domain Ocular Coherence Tomography (SD OCT) scanner to record the volume of the ONL in 194 eyes of 100 patients who have been on Hydroxychloroquine for 5 years or more. Volume data was analysed using the Statistical Package for Social Sciences (SPSS), we used logistic regression method to determine the probability of developing maculopathy based on the degree of reduction of the ONL volume. We correlated the loss of ONL to changes in visual fields.

**Results:** Mean age: 62.2 years, 20% males and 80% females. Diagnosis: 68% rheumatoid arthritis, 14% Sjogren's syndrome, 16% Systemic Lupus and 2% others. Mean duration of use was 6.3 years. Logistic regression results show strong negative correlation between the ONL volume and probability of toxicity, a reduction of 0.5 mm<sup>3</sup> of the ONL volume carries a 51% chance of developing maculopathy ( $P = 0.001$ ), the Hosmer-Lemeshow test indicates a high significance with a high P value of 0.61. Onset and progression of visual field defects strongly correlate to loss of ONL volume of 50% or more ( $P = 0.000$ ) and age above 35 years ( $P = 0.0001$ ).

**Conclusion:** Outer nuclear layer volume reduction provides an accurate and objective way of predicting the development of hydroxychloroquine retinopathy, this method also helps building a cooperative relationship between ophthalmologists and rheumatologists to establish an effective screening service.

#### REFERENCES:

- [1] I. H. Yusuf, S. Sharma, R. Luqmani and S. M. Downes, *Hydroxychloroquine retinopathy*, 2017.
- [2] M. Wiącek, D. Bobrowska-Snarska, W. Lubiński, M. Brzosko and M. Modrzejewska, *What is new in recommendations on ophthalmological screening in patients treated with chloroquine and hydroxychloroquine? Update and literature review*, 2017.
- [3] G. P. Smith, *High-risk category for early annual ophthalmology screening of patients receiving hydroxychloroquine*, 2017.
- [4] G. Ruberto, C. Bruttini, C. Tinelli, L. Cavagna, A. Bianchi and G. Milano, "Early morpho-functional changes in patients treated with hydroxychloroquine: a prospective cohort study".
- [5] J. A. Rodriguez-Padilla, T. R. Hedges, B. Monson, V. Srinivasan, M. Wojtkowski, E. Reichel, J. S. Duker, J. S. Schuman and J. G. Fujimoto, "High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy," *Archives of Ophthalmology*, 2007.
- [6] K. C. Iselin, P. Marti and M. Pless, "Hydroxychloroquine-Induced Retinal Toxicity," *Klinische Monatsblätter für Augenheilkunde*, 2016.
- [7] F. Babeau, T. Busetto, C. Hamel, M. Villain and V. Daien, *Adaptive optics: a tool for screening hydroxychloroquine-induced maculopathy?*, 2017.
- [8] "Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Screening," 2018.

**Disclosure of Interests:** Hani Hasan Grant/research support from: Bayer, Heidelberg Engineering, Speakers bureau: Bayer, Khin Yein: None declared, Tareq Mudawi: None declared, Elizabeth Price: None declared, Guy Smith: None declared

DOI: 10.1136/annrheumdis-2019-eular.4044

FRI0640

### COMPARING DISEASE ACTIVITY IN THE WRIST BY REPEAT SYNOVIAL BIOPSIES, RAMRIS MAGNETIC RESONANCE SCORE AND EULAR-OMERACT ULTRASOUND SCORE: A 6-MONTH PROSPECTIVE TRIAL IN EARLY AND LONGSTANDING RHEUMATOID ARTHRITIS

Søren Andreas Just<sup>1,2</sup>, Christian Nielsen<sup>3</sup>, Jens Werlinrud<sup>4</sup>, Pia Veldt Larsen<sup>5</sup>, Camilla Schufri Klinkby<sup>2</sup>, Henrik Daa Schröder<sup>6</sup>, Frances Humby<sup>7</sup>, Trine Torfing<sup>8</sup>, Hanne Merete Lindegaard<sup>2</sup>. <sup>1</sup>Svendborg Hospital, Odense University Hospital, Department of Medicine, Svendborg, Denmark; <sup>2</sup>Odense University Hospital, Department of Rheumatology, Odense, Denmark; <sup>3</sup>Odense University Hospital, Department of Clinical Immunology, Odense, Denmark; <sup>4</sup>Odense University Hospital, Department of Orthopedics, Odense, Denmark; <sup>5</sup>Epidemiology and Biostatistics, Department of Public Health, Odense, Denmark; <sup>6</sup>Odense University Hospital, Department of Pathology, Odense, Denmark; <sup>7</sup>William Harvey Research Institute, Barts and The London School of Medicine and Dentistry Queen Mary University of London, London, United Kingdom; <sup>8</sup>Odense University Hospital, Department of Radiology, Odense, Denmark

**Background:** Standardized scoring systems for Rheumatoid Arthritis (RA) joint disease activity are validated in different imaging modalities and